Last updated: August 24, 2026
Tribenzor, Daiichi Sankyo’s fixed-dose combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, moved from branded growth product to mature multisource medicine after the loss of meaningful U.S. exclusivity. Its commercial value depended on the broader Benicar franchise rather than on separately reported Tribenzor sales. Generic competition now limits pricing power, while the product remains clinically relevant for patients requiring triple-drug hypertension therapy.
What is Tribenzor and how is it used?
Tribenzor combines three antihypertensive agents:
| Component |
Drug class |
Primary role |
| Olmesartan medoxomil |
Angiotensin II receptor blocker |
Reduces angiotensin-mediated vasoconstriction |
| Amlodipine |
Dihydropyridine calcium-channel blocker |
Produces arterial vasodilation |
| Hydrochlorothiazide |
Thiazide diuretic |
Increases sodium and fluid excretion |
The U.S. Food and Drug Administration approved Tribenzor in July 2010 under NDA 022581 for adults whose blood pressure is inadequately controlled on dual therapy or who are already receiving the three components at the same doses. The product is available in four strengths:
- 20 mg olmesartan medoxomil / 5 mg amlodipine / 12.5 mg hydrochlorothiazide
- 40 mg / 5 mg / 12.5 mg
- 40 mg / 10 mg / 12.5 mg
- 40 mg / 10 mg / 25 mg
The maximum labeled dose is 40/10/25 mg once daily. The label includes warnings involving fetal toxicity, hypotension, renal impairment, electrolyte abnormalities and acute angle-closure glaucoma. It also carries the class-specific olmesartan warning concerning sprue-like enteropathy. (U.S. Food and Drug Administration, 2010)
When did Tribenzor lose exclusivity?
Tribenzor received three years of FDA new-drug exclusivity tied to the combination product. That regulatory exclusivity would have expired in 2013, assuming no pediatric extension. Regulatory exclusivity did not prevent generic manufacturers from challenging or designing around Orange Book-listed patents after the statutory exclusivity period.
The commercial protection timeline was approximately:
| Event |
Date |
| FDA approval |
July 2010 |
| Expected end of three-year new-drug exclusivity |
July 2013 |
| Expected end of principal U.S. patent protection |
2023, subject to patent-term adjustments and listed claims |
| Generic market phase |
Mid-to-late 2010s onward |
| Current commercial status |
Mature, genericized fixed-dose combination |
The relevant protection period was not equivalent to a guaranteed monopoly through 2023. Generic applicants could file Paragraph IV certifications, litigate patent validity or enforceability, and potentially obtain approval before the nominal patent expiration date. The practical loss of exclusivity therefore depended on ANDA litigation, settlements, approvals and launch decisions.
What patents protected Tribenzor?
Tribenzor’s protection was based on a combination of regulatory exclusivity and patents covering the fixed-dose formulation and related pharmaceutical composition. The product did not rely exclusively on the underlying olmesartan, amlodipine or hydrochlorothiazide compound patents. Those active ingredients had separate development and patent histories, many of which were older than the Tribenzor combination.
The key patent categories were:
- Combination-composition claims covering olmesartan medoxomil, amlodipine and hydrochlorothiazide.
- Pharmaceutical formulation claims covering the fixed-dose tablet.
- Manufacturing and dosage-form claims associated with producing the combination.
- Method-of-use claims directed to treatment of hypertension.
The FDA Orange Book is the controlling public source for determining which patents were listed against NDA 022581 at a particular time. Orange Book listings can change through patent expiration, delisting, corrections and regulatory updates. A historical patent review should therefore distinguish between patents listed at approval, patents remaining during an ANDA challenge and patents currently listed. (U.S. Food and Drug Administration, 2024a)
The practical patent conclusion is clear: Tribenzor’s combination patent estate delayed generic entry but no longer creates a material U.S. barrier to multisource competition. The product has passed from patent-protected branded medicine into lifecycle management and generic substitution.
How many patents cover Tribenzor?
The number depends on the review date and whether the analysis includes expired patents, Orange Book-listed patents, continuation applications and patents covering the individual components. A current Orange Book count and a historical prosecution count will produce different results.
For commercial analysis, the more relevant question is whether any unexpired, enforceable patent blocks an approved generic. Tribenzor no longer has the exclusivity profile of a newly launched fixed-dose combination. The remaining risk is product-specific and jurisdiction-specific rather than a broad U.S. monopoly.
The underlying component estate is also largely mature:
- Olmesartan medoxomil is an older ARB with extensive generic availability.
- Amlodipine has been generic for many years.
- Hydrochlorothiazide is a long-established generic diuretic.
This makes composition and formulation claims more important than compound claims in assessing residual protection.
What is the Orange Book status of Tribenzor?
Tribenzor is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under NDA 022581. The Orange Book identifies the reference listed drug against which ANDA applicants establish bioequivalence.
Orange Book status has three commercial implications:
- It identifies the reference product for generic approval.
- It records patents and exclusivity associated with the NDA.
- It provides the framework for Paragraph IV patent certifications.
The Orange Book does not establish that every listed patent is valid or infringed. Patent validity and infringement remain matters for courts. Nor does an Orange Book entry alone determine whether generic manufacturers will launch at risk or wait for patent expiry. (U.S. Food and Drug Administration, 2024a)
Which companies challenged Tribenzor patents?
Generic competition has come from manufacturers participating in the U.S. ANDA system for olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Public FDA records show generic approvals for the combination product from multiple manufacturers over time, including companies active in the U.S. cardiovascular market.
The commercial challenger group has included large and mid-sized generic suppliers such as:
- Lupin
- Torrent Pharmaceuticals
- Teva Pharmaceuticals
- Dr. Reddy’s Laboratories
- Mylan or Viatris-related entities
- Other ANDA sponsors appearing in FDA approval records
An ANDA approval does not necessarily mean the sponsor prevailed in a litigated Paragraph IV case. A sponsor may have filed a Paragraph III certification, launched after patent expiry or obtained approval following a settlement. The public record should be read at the individual ANDA and patent level rather than treating all generic approvals as evidence of a single litigation outcome.
What generic entry risks exist for Tribenzor?
Generic entry risk is high. The main factors are:
| Risk factor |
Assessment |
| Active-ingredient barriers |
Low |
| Formulation complexity |
Low to moderate |
| Manufacturing difficulty |
Moderate |
| Bioequivalence burden |
Manageable |
| Remaining U.S. patent barrier |
Low |
| Pricing pressure |
High |
| Substitution risk |
High |
Tribenzor is an immediate-release oral tablet rather than a biologic, depot injection or complex delivery system. Generic manufacturers do not face the manufacturing and analytical barriers associated with sterile injectables, inhaled products or modified-release systems.
The main technical challenge is demonstrating bioequivalence across a three-active-ingredient product with multiple strengths. That challenge is commercially manageable because the dosage form is conventional and each component has a long regulatory history.
Once several suppliers enter, pharmacy benefit managers, wholesalers and retail pharmacies can shift volume toward lower-cost alternatives. The reference product generally loses share even if the branded label remains available.
What formulations are protected by Tribenzor patents?
The principal formulation concept is a single tablet containing the three active ingredients. Formulation claims can cover:
- The relative amounts of olmesartan medoxomil, amlodipine and hydrochlorothiazide.
- Tablet composition and excipients.
- Uniform distribution of low-dose amlodipine within the tablet.
- Dissolution and release characteristics.
- Manufacturing processes that produce acceptable content uniformity and stability.
The formulation is commercially useful because it reduces pill burden. Its value is weaker after generic approval because an ANDA sponsor can market an equivalent tablet without reproducing every nonessential aspect of the brand formulation, provided it meets the applicable pharmaceutical and bioequivalence requirements.
What is the FDA regulatory status of Tribenzor?
Tribenzor remains an FDA-approved prescription product for hypertension. Approval does not imply current market exclusivity. The product’s regulatory status is separate from its commercial status.
The FDA-approved indication is narrower than a general cardiovascular-risk claim. Tribenzor treats hypertension; it is not approved to reduce cardiovascular events independently of blood-pressure control. Its use is generally positioned after inadequate control with dual therapy or in patients already stabilized on the three ingredients. (U.S. Food and Drug Administration, 2010)
The product is also exposed to class-wide prescribing considerations, including:
- Renal monitoring
- Potassium and sodium abnormalities
- Volume depletion
- Edema from amlodipine
- Hyperuricemia from hydrochlorothiazide
- Fetal toxicity from renin-angiotensin-system blockade
How does Tribenzor compare with competing hypertension combinations?
Tribenzor competes against both branded and generic triple combinations.
| Product or strategy |
Components |
Commercial position |
| Tribenzor |
Olmesartan / amlodipine / HCTZ |
Mature branded and generic fixed-dose combination |
| Generic equivalents |
Same three components |
Lowest-cost direct substitutes |
| Exforge HCT |
Valsartan / amlodipine / HCTZ |
Competing ARB-based triple therapy |
| Generic equivalents of Exforge HCT |
Valsartan / amlodipine / HCTZ |
Broad generic pressure |
| Separate tablets |
Any ARB, CCB and diuretic |
Flexible dosing, usually low cost |
| ACE inhibitor combinations |
ACE inhibitor / CCB / diuretic |
Alternative guideline-based therapy |
Tribenzor’s principal differentiation is convenience, not molecular novelty. Doctors may still select it for patients who benefit from the olmesartan component or prefer the specific dose combination. Generic availability sharply reduces the ability to charge a premium for that convenience.
What patent litigation affects Tribenzor?
Tribenzor’s current commercial risk is primarily generic erosion rather than active brand-defense litigation. The important legal events historically would have been Paragraph IV certifications, ANDA litigation, settlement agreements and any authorized-generic arrangement.
No current brand-blocking litigation is evident from the FDA product status and the mature generic market position. Any historical settlement must be evaluated against its specific parties, patents, launch date and restrictions. A settlement involving one ANDA sponsor would not necessarily prevent other generic approvals.
For investors and licensing teams, the critical legal questions are:
- Whether the relevant patent was listed against NDA 022581.
- Whether the generic applicant certified under Paragraph III or Paragraph IV.
- Whether litigation triggered a 30-month stay.
- Whether the patent survived validity and infringement challenges.
- Whether the settlement permitted an earlier launch.
- Whether authorized-generic supply changed the effective entry date.
Did Tribenzor have licensing deals?
Tribenzor was developed and marketed within Daiichi Sankyo’s Benicar and cardiovascular franchise. The product did not become a major standalone licensing asset comparable to a novel biologic or specialty drug.
Its commercial value was linked to Daiichi Sankyo’s broader olmesartan franchise, which included Benicar, Benicar HCT and related products. Company financial disclosures generally reported franchise or regional sales rather than a separately audited Tribenzor revenue line. (Daiichi Sankyo Co., Ltd., 2011, 2012)
There is no clear basis for assigning a separate, publicly reported global revenue figure to Tribenzor. Product-level revenue estimates should therefore be treated as modeled allocations rather than reported financial data.
What was Tribenzor’s financial trajectory?
Tribenzor’s financial trajectory followed a conventional fixed-dose combination lifecycle:
Launch and franchise expansion: 2010-2012
The product expanded the olmesartan franchise into patients requiring three-drug therapy. Initial uptake benefited from:
- Existing physician familiarity with Benicar.
- The convenience of one tablet.
- The established use of amlodipine and hydrochlorothiazide.
- Promotion through the broader hypertension franchise.
Peak commercial period: approximately 2011-2013
The strongest revenue contribution occurred before broad generic erosion of the component and combination markets. Tribenzor was more valuable as a franchise-defense product than as an independent blockbuster.
Patent transition: approximately 2013-2023
The end of three-year exclusivity allowed generic development, while formulation patents provided the principal remaining U.S. protection. Pricing and volume became increasingly dependent on formulary placement, brand loyalty and the timing of ANDA approvals.
Mature generic phase: 2023 onward
The product now faces high substitution pressure. Net sales are likely to be concentrated in residual branded prescriptions, contracts that preserve brand dispensing and markets where generic availability is incomplete. Gross revenue may remain measurable, but margin quality is structurally weaker.
How strong is the Tribenzor patent estate?
The estate is commercially weak today but was strategically useful during the launch period.
| Dimension |
Rating |
Rationale |
| Novel active ingredient protection |
Weak |
All three ingredients are mature molecules |
| Fixed-dose combination protection |
Moderate historically |
Combination and formulation claims supported launch protection |
| Manufacturing complexity |
Low to moderate |
Conventional oral tablet |
| Regulatory exclusivity |
Expired |
Three-year exclusivity ended years ago |
| Generic substitution resistance |
Low |
Multiple component and combination alternatives exist |
| Remaining U.S. revenue protection |
Low |
Product is in the mature generic phase |
| International protection |
Country-specific |
Patent and launch dates vary by jurisdiction |
The estate’s strongest commercial period was before generic entry. Its present value lies mainly in residual trademarks, manufacturing know-how, supply relationships and market access rather than in enforceable exclusion.
What is the outlook for Tribenzor revenue?
Tribenzor revenue should continue to decline or remain limited in markets with broad generic penetration. The likely revenue pattern is:
- Lower average selling prices.
- Reduced branded prescription volume.
- Greater dependence on institutional and managed-care contracts.
- Continued demand for the therapeutic combination.
- Persistent substitution toward separate generic tablets or generic triple-combination tablets.
The broader hypertension market remains large, but that market size does not translate into strong Tribenzor economics. Generic olmesartan, amlodipine and hydrochlorothiazide provide inexpensive substitutes. Physicians can also titrate each ingredient separately, which weakens the fixed-dose product’s pricing leverage.
There is no biosimilar risk because Tribenzor is a chemically synthesized small-molecule tablet. Its relevant competitive threats are ANDA-approved generics, therapeutic substitution and low-cost separate-component regimens.
Key Takeaways
- Tribenzor is a fixed-dose olmesartan, amlodipine and hydrochlorothiazide tablet approved by the FDA in 2010.
- Its three-year regulatory exclusivity expired in 2013.
- The principal commercial patent protection was associated with the combination and formulation and extended approximately into 2023, subject to individual patent terms.
- Tribenzor is now a mature, genericized product with limited pricing power.
- The product has no biosimilar exposure; its risk comes from ANDA generics and therapeutic substitution.
- Daiichi Sankyo did not separately disclose Tribenzor revenue in a way that supports a definitive standalone global sales figure.
- The product’s remaining value is concentrated in brand recognition, residual prescriptions, supply contracts and convenience.
- The patent estate has low current blocking strength despite having supported the original franchise strategy.
FAQs
Is Tribenzor still available in the United States?
Yes. FDA-approved branded and generic versions may be available, although pharmacy inventory and manufacturer participation can change over time.
Can patients substitute generic drugs for Tribenzor?
Yes. Generic olmesartan, amlodipine and hydrochlorothiazide products can be prescribed separately, and approved generic fixed-dose combinations may be substituted where state law, payer rules and prescriber instructions permit.
Is Tribenzor a biologic or biosimilar product?
No. Tribenzor is a conventional small-molecule tablet. Biosimilar approval rules do not apply.
Does Tribenzor have pediatric exclusivity?
The original approval did not create a material pediatric-exclusivity extension in the commercial timeline. Its relevant U.S. exclusivity has expired.
What is the principal investment risk for Tribenzor?
The principal risk is continued generic price and volume erosion. The product lacks a new chemical entity, biologic, device or complex manufacturing barrier that could support durable premium pricing.
References
-
Daiichi Sankyo Co., Ltd. (2011). Annual report 2011. Daiichi Sankyo Co., Ltd.
-
Daiichi Sankyo Co., Ltd. (2012). Annual report 2012. Daiichi Sankyo Co., Ltd.
-
U.S. Food and Drug Administration. (2010). Tribenzor prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
